Investors Presentation
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx Ltd shared an investor presentation covering FY 2024-25 results. Consolidated revenue rose to Rs. 96.47 crore (from Rs. 74.12 crore), while profit after tax jumped to Rs. 47.69 crore (from Rs. 32.10 crore), pushing EPS to Rs. 55.66. The Molecular Diagnostics (MDx) division was the main growth driver, with revenue up 38.5% to Rs. 84.28 crore, EBITDA up 42.7%, and PAT up 46.8% year-on-year. Export sales nearly doubled (~97% growth) to Rs. 17.10 crore, led by the UK subsidiary TRUPCR Europe which posted over 90% revenue growth. The board has recommended a final dividend of Rs. 4 per share (40%). Management highlighted 15+ long-term reagent-rental contracts, pipeline of new product launches (Digital PCR, NGS panels), and continued pursuit of M&A opportunities in the IVD space.
Strong FY 2024-25 performance with healthy revenue, profit, and margin growth in the core MDx business signals positive momentum for shareholders. Guidance for 15-20% MDx growth and 20-25% international growth in FY 2025-26, along with new product pipeline and dividend announcement, is likely to be viewed positively by investors.